MINIPRESS TABLET 1 mg

국가: 싱가포르

언어: 영어

출처: HSA (Health Sciences Authority)

유효 성분:

PRAZOSIN HCl EQV PRAZOSIN

제공처:

PFIZER PRIVATE LIMITED

ATC 코드:

C02CA01

복용량:

1 mg

약제 형태:

TABLET

관리 경로:

ORAL

처방전 유형:

Prescription Only

Manufactured by:

PFIZER AUSTRALIA PTY LTD

승인 날짜:

1988-05-10

환자 정보 전단

1.  NAME OF MEDICINAL PRODUCT  

MINIPRESS. 

2.  QUALITATIVE AND QUANTITATIVE COMPOSITION  

Each prazosin hydrochloride tablet contains the equivalent of 1,
2 and 5 mg of prazosin free 
base. 

3.  PHARMACEUTICAL FORM  

Tablets. 

4.  CLINICAL PARTICULARS 

4.1 Therapeutic Indications  

_Hypertension  _

Prazosin hydrochloride is indicated in the
treatment of all grades of essential (primary) 
hypertension and of all
grades of secondary hypertension of varied etiology. It
can be used as 
the initial and sole agent or it may be employed in a
treatment program in conjunction with a 
diuretic and/or other antihypertensive drugs as needed for
proper patient response.  
_ _
_Left Ventricular Failure  _

Prazosin hydrochloride is indicated in the treatment of left
ventricular failure. Prazosin 
hydrochloride may be added to the therapeutic regimen in
those patients who have not shown 
a satisfactory response or who have become refractory to conventional therapy with
diuretics, 
with or without cardiac glycosides.  
_ _
_Benign Prostatic Hyperplasia (BPH) _ 

Prazosin hydrochloride is indicated as an
adjunct in the symptomatic treatment of urinary 
obstruction caused by benign prostatic hyperplasia. It is
also of value in patients awaiting 
prostatic surgery.  

_Raynaud’s Phenomenon and Raynaud’s Disease _ 

Prazosin hydrochloride is indicated in the treatment
of Raynaud’s phenomenon and 
Raynaud’s disease. 

4.2 Posology and Method of Administration 

There is evidence that toleration is best when therapy is
initiated with a low starting dose of 
prazosin hydrochloride (see section 4.4 Special Warnings and
Special Precautions for Use).  

During the first week, the dosage of prazosin hydrochloride should be adjusted according to 
the patient’s individual toleration.
Thereafter the d